These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37603172)

  • 1. Modeling of Transmembrane Domain and Full-Length TLRs in Membrane Models.
    Matamoros-Recio A; Mínguez-Toral M; Martín-Santamaría S
    Methods Mol Biol; 2023; 2700():3-38. PubMed ID: 37603172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full-Atom Model of the Agonist LPS-Bound Toll-like Receptor 4 Dimer in a Membrane Environment.
    Matamoros-Recio A; Franco-Gonzalez JF; Perez-Regidor L; Billod JM; Guzman-Caldentey J; Martin-Santamaria S
    Chemistry; 2021 Nov; 27(62):15406-15425. PubMed ID: 34569111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
    Mishra V; Pathak C
    J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Insight Into the Structural Organization of Full-Length Toll-Like Receptor 4 Dimer in a Model Phospholipid Bilayer.
    Patra MC; Kwon HK; Batool M; Choi S
    Front Immunol; 2018; 9():489. PubMed ID: 29593733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational Approaches to Toll-Like Receptor 4 Modulation.
    Billod JM; Lacetera A; Guzmán-Caldentey J; Martín-Santamaría S
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.
    Okamoto N; Mizote K; Honda H; Saeki A; Watanabe Y; Yamaguchi-Miyamoto T; Fukui R; Tanimura N; Motoi Y; Akashi-Takamura S; Kato T; Fujishita S; Kimura T; Ohto U; Shimizu T; Hirokawa T; Miyake K; Fukase K; Fujimoto Y; Nagai Y; Takatsu K
    J Biol Chem; 2017 Sep; 292(37):15378-15394. PubMed ID: 28754693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Thermodynamic Funnel Drives Bacterial Lipopolysaccharide Transfer in the TLR4 Pathway.
    Huber RG; Berglund NA; Kargas V; Marzinek JK; Holdbrook DA; Khalid S; Piggot TJ; Schmidtchen A; Bond PJ
    Structure; 2018 Aug; 26(8):1151-1161.e4. PubMed ID: 29779787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.
    Peri F; Piazza M
    Biotechnol Adv; 2012; 30(1):251-60. PubMed ID: 21664961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polar SxxS motif drives assembly of the transmembrane domains of Toll-like receptor 4.
    Kargas V; Marzinek JK; Holdbrook DA; Yin H; Ford RC; Bond PJ
    Biochim Biophys Acta Biomembr; 2017 Oct; 1859(10):2086-2095. PubMed ID: 28739292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of toll-like receptor 4. Insights from x-ray crystallography and molecular modeling.
    Klett J; Reeves J; Oberhauser N; Pérez-Regidor L; Martín-Santamaria S
    Curr Top Med Chem; 2014; 14(23):2672-83. PubMed ID: 25515751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Toll-like receptors by Burkholderia pseudomallei.
    West TE; Ernst RK; Jansson-Hutson MJ; Skerrett SJ
    BMC Immunol; 2008 Aug; 9():46. PubMed ID: 18691413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics.
    Heine H; Adanitsch F; Peternelj TT; Haegman M; Kasper C; Ittig S; Beyaert R; Jerala R; Zamyatina A
    Front Immunol; 2021; 12():631797. PubMed ID: 33815382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipopolysaccharide Recognition in the Crossroads of TLR4 and Caspase-4/11 Mediated Inflammatory Pathways.
    Zamyatina A; Heine H
    Front Immunol; 2020; 11():585146. PubMed ID: 33329561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the Innate Immune Recognition of Opioid Inactive Isomer (+)-Naltrexone Derived Toll-like Receptor 4 (TLR4) Antagonists.
    Zhang X; Cui F; Chen H; Zhang T; Yang K; Wang Y; Jiang Z; Rice KC; Watkins LR; Hutchinson MR; Li Y; Peng Y; Wang X
    J Chem Inf Model; 2018 Apr; 58(4):816-825. PubMed ID: 29518316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the LPS/TLR4 signal pathway with small molecules.
    Peri F; Piazza M; Calabrese V; Damore G; Cighetti R
    Biochem Soc Trans; 2010 Oct; 38(5):1390-5. PubMed ID: 20863319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structural basis for endotoxin-induced allosteric regulation of the Toll-like receptor 4 (TLR4) innate immune receptor.
    Paramo T; Piggot TJ; Bryant CE; Bond PJ
    J Biol Chem; 2013 Dec; 288(51):36215-25. PubMed ID: 24178299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico approach to inhibition of signaling pathways of Toll-like receptors 2 and 4 by ST2L.
    Basith S; Manavalan B; Govindaraj RG; Choi S
    PLoS One; 2011; 6(8):e23989. PubMed ID: 21897866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAF3-interacting JNK-activating modulator promotes inflammation by stimulating translocation of Toll-like receptor 4 to lipid rafts.
    Li Y; Guan J; Wang W; Hou C; Zhou L; Ma J; Cheng Y; Jiao S; Zhou Z
    J Biol Chem; 2019 Feb; 294(8):2744-2756. PubMed ID: 30573680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MD-2: the Toll 'gatekeeper' in endotoxin signalling.
    Gangloff M; Gay NJ
    Trends Biochem Sci; 2004 Jun; 29(6):294-300. PubMed ID: 15276183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family.
    Martin MU; Wesche H
    Biochim Biophys Acta; 2002 Nov; 1592(3):265-80. PubMed ID: 12421671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.